Information Links
Mims
Main Navigation
Drugs
Conditions
ArticlesGuidelines - Eye
Quick-reference summaries of key national treatment guidance for ophthalmic conditions including macular degeneration and dry eye.
MIMS summaries
At-a-glance summaries of authoritative evidence-based clinical guidelines for ophthalmic conditions commonly encountered in primary care.
Current Medical Standards of Fitness to Drive (DVLA Guidance)
Key advice from DVLA on fitness to drive.
NICE technology appraisals
Decisions by the National Institute for Health and Care Excellence on NHS access to treatments for ophthalmic conditions.
-
Aflibercept for Treating Visual Impairment Caused by Macular Oedema after Branch Retinal Vein Occlusion (TA409)
-
Ciclosporin for Treating Dry Eye Disease That Has Not Improved Despite Treatment with Artificial Tears (TA369)
-
Dexamethasone Intravitreal Implant For Treating Diabetic Macular Oedema (TA349)
-
Aflibercept for Treating Diabetic Macular Oedema (TA346)
-
Aflibercept for Treating Visual Impairment Caused by Macular Oedema Secondary to Central Retinal Vein Occlusion (TA305)
-
Ranibizumab for Treating Choroidal Neovascularisation Associated with Pathological Myopia (TA298)
-
Ocriplasmin for Treating Vitreomacular Traction (TA297)
-
Aflibercept Solution for Injection for Treating Wet Age-Related Macular Degeneration (TA294)
-
Ranibizumab for Treating Visual Impairment Caused By Macular Oedema Secondary to Retinal Vein Occlusion (TA283)
-
Ranibizumab for the Treatment of Diabetic Macular Oedema (TA274 [Rapid Review of TA237])
-
Fluocinolone Acetonide Intravitreal Implant for the Treatment of Chronic Diabetic Macular Oedema after an Inadequate Response to Prior Therapy (TA271])
-
Ranibizumab for the Treatment of Diabetic Macular Oedema (TA237)
-
Macular Degeneration, Age-Related: Photodynamic Therapy (NICE)
MIMS Clinics
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
